Literature DB >> 9795384

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.

A Pinter1, W J Honnen, S C Kayman, O Trochev, Z Wu.   

Abstract

Although it is known that some human immune sera possess potent neutralizing activities for primary viruses, the identity of the target epitopes mediating this neutralization is unknown, and currently available immunogens have not been able to induce such activities. Using recombinant fusion glycoproteins expressing native V1/V2 domains of gp120 we have found that sera from a subset of HIV-1-infected humans contain antibodies that recognize broadly conserved V1/V2 epitopes. Such antibodies were isolated from one human serum by affinity chromatography on a column containing a V1/V2 fusion protein, and shown to efficiently neutralize several macrophage-tropic HIV-1 isolates. Rodents immunized with the purified V1/V2 fusion protein produced antibodies reactive with unrelated V1/V2 fusion proteins and with heterologous gp120s. V1/V2-specific immunoglobulins isolated from sera of these animals by affinity chromatography also possessed potent neutralization activity for several primary HIV-1 isolates. These results indicate that the V1/V2 domain of HIV-1 gp120 contains conserved epitopes that mediate potent neutralization of primary viruses, and suggest that subunit vaccines that efficiently induce such antibodies may provide protective humoral immunity against clinically relevant HIV-1 isolates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795384     DOI: 10.1016/s0264-410x(98)00182-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

2.  The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Authors:  Abraham Pinter; William J Honnen; Paul D'Agostino; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 3.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

4.  Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.

Authors:  S Munir Alam; Hua-Xin Liao; Georgia D Tomaras; Mattia Bonsignori; Chun-Yen Tsao; Kwan-Ki Hwang; Haiyan Chen; Krissey E Lloyd; Cindy Bowman; Laura Sutherland; Thomas L Jeffries; Daniel M Kozink; Shelley Stewart; Kara Anasti; Frederick H Jaeger; Robert Parks; Nicole L Yates; R Glenn Overman; Faruk Sinangil; Phillip W Berman; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Nicos Karasavva; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Susan Zolla-Pazner; Sampa Santra; Norman L Letvin; Stephen C Harrison; Barton F Haynes
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

5.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

Review 6.  Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.

Authors:  David R Martinez; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

7.  The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system.

Authors:  S C Kayman; H Park; M Saxon; A Pinter
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

9.  Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Authors:  Javier F Morales; Bin Yu; Gerardo Perez; Kathryn A Mesa; David L Alexander; Phillip W Berman
Journal:  Mol Immunol       Date:  2016-07-21       Impact factor: 4.407

10.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.